Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin US00287Y1091
Ticker ABBV
Company ABBVIE
Currency $
Price
Aware Investor Index (AII) 761.8285
Recommendation STRONG BUY
P/E 23.10
ROE 100.00 %
Capitalization 105,128,000,000 $
Dividend Yield 5.81 %
P/S 3.21
AII Position 9
P/E Position 326
ROE Position 21
Capitalization Position 98
Dividend Yield Position 66
Sales 32,753,000,000 $
10-Year Average Earnings 4,551,700,000 $
Shares Outstanding 1,546,000,000
Equity -8,446,000,000 $
Dividend per Share 3.95 $
Industry Pharmaceutical
Country United States
ABBVIE Investor Relations Web Site http://www.abbvieinvestor.com







Sales:

YEAR MONTH AMOUNT
2018 12 32,753,000,000.00 $
2017 12 28,216,000,000.00 $
2016 12 25,638,000,000.00 $
2015 12 22,859,000,000.00 $
2014 12 19,960,000,000.00 $
2013 12 18,790,000,000.00 $
2012 12 18,380,000,000.00 $
2011 12 17,444,000,000.00 $
2010 12 15,638,000,000.00 $
2009 12 14,214,000,000.00 $

Earnings:

YEAR MONTH AMOUNT
2018 12 5,687,000,000.00 $
2017 12 5,309,000,000.00 $
2016 12 5,953,000,000.00 $
2015 12 5,144,000,000.00 $
2014 12 1,774,000,000.00 $
2013 12 4,128,000,000.00 $
2012 12 5,275,000,000.00 $
2011 12 3,433,000,000.00 $
2010 12 4,178,000,000.00 $
2009 12 4,636,000,000.00 $

Equity:

YEAR MONTH AMOUNT
2018 12 -8,446,000,000.00 $
2017 12 5,097,000,000.00 $
2016 12 4,636,000,000.00 $
2015 12 3,945,000,000.00 $
2014 12 1,742,000,000.00 $
2013 12 4,492,000,000.00 $
2012 12 3,363,000,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2018 12 1,546,000,000
2017 12 1,603,000,000
2016 12 1,631,000,000
2015 12 1,637,000,000
2014 12 1,610,000,000
2013 12 1,604,000,000
2012 12 1,577,000,000

 












Bloomberg News for ABBVIE:



Google News for ABBVIE:

Yahoo Finance - 11 hours ago
AbbVie (ABBV) Earnings Expected to Grow: Should You Buy?
The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ...
Yahoo Finance - 2 days ago
AbbVie (ABBV) is an Incredible Growth Stock: 3 Reasons Why
Our proprietary system currently recommends AbbVie (ABBV) as one such stock. This company not only has a favorable Growth Score, but also ...
Yahoo Finance - 3 days ago
AbbVie (ABBV) Acquires Mavupharma to Boost Cancer Portfolio
AbbVie Inc. ABBV announced that it has acquired Seattle-based, privately held company Mavupharma to develop novel treatments for cancer ...
Yahoo Finance - 2 days ago
Should Value Investors Buy AbbVie (ABBV) Stock?
One company value investors might notice is AbbVie (ABBV). ABBV is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for ...
Yahoo Finance - 4 days ago
AbbVie (ABBV) Gains But Lags Market: What You Should Know
AbbVie (ABBV) closed the most recent trading day at $70.29, moving +0.01% from the previous trading session. This move lagged the S&P ...
Yahoo Finance - 8 Jul 2019
AbbVie (ABBV) Shares Down So Far This Year: Here's Why
AbbVie, Inc. ABBV stock has declined 20.8% this year so far against an ... AbbVie is heavily dependent on Humira and is looking to diversify its ...
Nasdaq - 2 days ago
AbbVie (ABBV) Upgraded to Buy: Here's What You Should Know
AbbVie (ABBV) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an ...
The InvestReporter - 4 hours ago
As Abbvie (ABBV) Market Value Declined, Tradition Capital ...
Tradition Capital Management Llc increased its stake in Abbvie Inc. (ABBV) by 9.51% based on its latest 2019Q1 regulatory filing with the SEC.
The InvestReporter - 4 hours ago
Griffin Asset Management Lowered Its Abbvie (ABBV) Holding; Hap ...
Griffin Asset Management Inc decreased Abbvie Inc. (ABBV) stake by 12.48% reported in 2019Q1 SEC filing. Griffin Asset Management Inc ...
Trent Times
AbbVie Stock Is Poised To Become A Top 5 Pharma — But Should ...
The deal helps AbbVie (ABBV) diversify away from Humira, a blockbuster drug that treats inflammatory conditions. Humira is already facing ...


Back